Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined Serum (1,3)-β-D-Glucan and Oral Wash PCR as a Noninvasive Diagnostic Strategy for Early Detection of <i>Pneumocystis jirovecii</i> Pneumonia: An Observational Retrospective Study.

Open forum infectious diseases·2026
Same author

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.

Blood advances·2025
Same author

Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study).

The Journal of antimicrobial chemotherapy·2025
Same author

Short- and long-term mortality in critically ill patients with solid cancer. The Vall d'Hebron Intensive Care Unit-Vall d'Hebron Institute of Oncology Cohort: a retrospective study.

Medicina intensiva·2025
Same author

Corrigendum to "Safety and effectiveness of isavuconazole in real-life non-neu tropenic patients" [International Journal of Infectious Diseases 144 (2024) 107070].

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2024
Same author

<i>Pseudomonas aeruginosa</i> Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy.

Microorganisms·2024
Same journal

New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons.

Enfermedades infecciosas y microbiologia clinica·2025
Same journal

[Description of 12 HIV-positive patients who have had the COVID-19 in our area].

Enfermedades infecciosas y microbiologia clinica·2024
Same journal

[SARS-CoV-2 infection as trigger multisystem inflammatory syndrome?]

Enfermedades infecciosas y microbiologia clinica·2024
Same journal

Impact of COVID-19 on Madrid hospital system.

Enfermedades infecciosas y microbiologia clinica·2024
Same journal

[COVID-19 and influenza A coinfection: a matter of principle].

Enfermedades infecciosas y microbiologia clinica·2024
Same journal

COVID and CARE®. Mobile application for monitoring SARS-CoV-2 positive patients after hospitalization.

Enfermedades infecciosas y microbiologia clinica·2024
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

[Antifungals for systemic use].

Isabel Ruiz-Camps1, Manuel Cuenca-Estrella

  • 1Servicio de Enfermedades Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España.

Enfermedades Infecciosas Y Microbiologia Clinica
|June 2, 2009
PubMed
Summary
This summary is machine-generated.

New antifungal drugs require tailored treatment for systemic fungal infections. Accurate fungal identification and susceptibility testing are crucial due to emerging resistance and varying global guidelines.

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

Related Experiment Videos

Last Updated: Jun 22, 2026

Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Context:

  • Recent advancements in antifungal agents have expanded therapeutic options for systemic fungal infections.
  • The increasing prevalence of antifungal resistance necessitates updated treatment strategies.
  • Geographical variations in treatment guidelines highlight the need for localized approaches.

Purpose:

  • To emphasize the evolving landscape of systemic fungal infection treatment.
  • To underscore the importance of accurate fungal identification and antifungal susceptibility testing.
  • To highlight the essential role of understanding antifungal agent properties and mechanisms in clinical practice.

Summary:

  • The development of new antifungal agents has led to a more diverse treatment landscape for systemic fungal infections.
  • Accurate identification of fungal pathogens and susceptibility testing are critical for effective treatment selection.
  • Emerging antifungal resistance and regional guideline differences necessitate a thorough understanding of antifungal drug profiles.

Impact:

  • Informed clinical decision-making for systemic fungal infections.
  • Improved patient outcomes through targeted antifungal therapy.
  • Adaptation of treatment protocols to combat antifungal resistance and geographical variations.